641 related articles for article (PubMed ID: 17956196)
1. Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
Iwamoto J; Takeda T; Sato Y
Expert Opin Pharmacother; 2007 Nov; 8(16):2743-56. PubMed ID: 17956196
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
3. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
4. Osteoporosis: non-hormonal treatment.
Rizzoli R
Climacteric; 2007 Oct; 10 Suppl 2():74-8. PubMed ID: 17882678
[TBL] [Abstract][Full Text] [Related]
5. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
6. Role of alendronate and risedronate in preventing and treating osteoporosis.
Peters ML; Leonard M; Licata AA
Cleve Clin J Med; 2001 Nov; 68(11):945-51. PubMed ID: 11718433
[TBL] [Abstract][Full Text] [Related]
7. Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis.
Migliore A; Broccoli S; Massafra U; Cassol M; Frediani B
Eur Rev Med Pharmacol Sci; 2013 Mar; 17(5):658-67. PubMed ID: 23543450
[TBL] [Abstract][Full Text] [Related]
8. Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.
Thomas T; Horlait S; Ringe JD; Abelson A; Gold DT; Atlan P; Lange JL
Osteoporos Int; 2013 Jan; 24(1):263-9. PubMed ID: 22736069
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
[TBL] [Abstract][Full Text] [Related]
10. The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Moshi MR; Nicolopoulos K; Stringer D; Ma N; Jenal M; Vreugdenburg T
Calcif Tissue Int; 2023 Jun; 112(6):631-646. PubMed ID: 37016189
[TBL] [Abstract][Full Text] [Related]
11. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
12. Developments in the pharmacotherapeutic management of osteoporosis.
Close P; Neuprez A; Reginster JY
Expert Opin Pharmacother; 2006 Aug; 7(12):1603-15. PubMed ID: 16872263
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of osteoporosis by risedronate-- speed, efficacy and safety].
Giljević Z; Vlak T
Reumatizam; 2006; 53(2):66-71. PubMed ID: 17580558
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis.
Jönsson B; Ström O; Eisman JA; Papaioannou A; Siris ES; Tosteson A; Kanis JA
Osteoporos Int; 2011 Mar; 22(3):967-82. PubMed ID: 20936401
[TBL] [Abstract][Full Text] [Related]
15. Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods.
Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
J Endocrinol Invest; 2014 Aug; 37(8):769-773. PubMed ID: 25008458
[TBL] [Abstract][Full Text] [Related]
16. Risedronate: a new oral bisphosphonate.
Umland EM; Boyce EG
Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
[TBL] [Abstract][Full Text] [Related]
17. [Austrian guidance for the pharmacologic treatment of osteoporosis in postmenopausal women: Addendum 2010].
Dimai HP; Pietschmann P; Resch H; Preisinger E; Fahrleitner-Pammer A; Dobnig H; Klaushofer K;
Wien Med Wochenschr; 2010 Dec; 160(21-22):586-9. PubMed ID: 21170699
[TBL] [Abstract][Full Text] [Related]
18. Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations.
Emkey R
MedGenMed; 2004 Jul; 6(3):6. PubMed ID: 15520628
[TBL] [Abstract][Full Text] [Related]
19. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.
Reginster JY
Drugs; 2011 Jan; 71(1):65-78. PubMed ID: 21175240
[TBL] [Abstract][Full Text] [Related]
20. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
Ringe JD; Möller G
Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
